The University of Chicago Header Logo

Connection

George Bakris to Adult

Back to Details
This is a "connection" page, showing publications George Bakris has written about Adult.
George Bakris
Connection Strength
1.910
Adult
  1. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024 03 05; 331(9):740-749.
    View in: PubMed
    Score: 0.063
  2. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747.
    View in: PubMed
    Score: 0.060
  3. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 07; 76(1):144-149.
    View in: PubMed
    Score: 0.049
  4. Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance. Hypertension. 2020 04; 75(4):943-944.
    View in: PubMed
    Score: 0.048
  5. Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254.
    View in: PubMed
    Score: 0.047
  6. Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. J Am Coll Cardiol. 2018 09 11; 72(11):1224-1226.
    View in: PubMed
    Score: 0.043
  7. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018 02 08; 378(6):497-499.
    View in: PubMed
    Score: 0.041
  8. Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. J Clin Hypertens (Greenwich). 2017 Nov; 19(11):1202-1203.
    View in: PubMed
    Score: 0.040
  9. Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. Circ J. 2017 Aug 25; 81(9):1337-1345.
    View in: PubMed
    Score: 0.039
  10. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ J. 2016 May 25; 80(6):1404-12.
    View in: PubMed
    Score: 0.037
  11. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14; 314(2):151-61.
    View in: PubMed
    Score: 0.035
  12. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321.
    View in: PubMed
    Score: 0.034
  13. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21; 36(4):219-27.
    View in: PubMed
    Score: 0.033
  14. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57.
    View in: PubMed
    Score: 0.032
  15. Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches. J Clin Hypertens (Greenwich). 2014 Feb; 16(2):141-8.
    View in: PubMed
    Score: 0.031
  16. Review of blood pressure control rates and outcomes. J Am Soc Hypertens. 2014 Feb; 8(2):127-41.
    View in: PubMed
    Score: 0.031
  17. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35.
    View in: PubMed
    Score: 0.028
  18. Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. J Womens Health (Larchmt). 2012 Sep; 21(9):917-24.
    View in: PubMed
    Score: 0.028
  19. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6.
    View in: PubMed
    Score: 0.027
  20. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83.
    View in: PubMed
    Score: 0.025
  21. Treatment and control of high blood pressure in adults. Cardiol Clin. 2010 Nov; 28(4):609-22.
    View in: PubMed
    Score: 0.025
  22. Hypertension following kidney injury. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):727-30.
    View in: PubMed
    Score: 0.025
  23. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):678-86.
    View in: PubMed
    Score: 0.024
  24. Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14.
    View in: PubMed
    Score: 0.024
  25. Pheochromocytoma in pregnancy: a case series and review. Hypertension. 2010 Mar; 55(3):600-6.
    View in: PubMed
    Score: 0.024
  26. Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease. Semin Nephrol. 2010 Jan; 30(1):66-73.
    View in: PubMed
    Score: 0.024
  27. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31.
    View in: PubMed
    Score: 0.022
  28. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Blood Purif. 2009; 27(2):231-4.
    View in: PubMed
    Score: 0.022
  29. CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Aug; 52(2):382-3.
    View in: PubMed
    Score: 0.021
  30. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S30-7.
    View in: PubMed
    Score: 0.021
  31. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr; 121(4):332-40.
    View in: PubMed
    Score: 0.021
  32. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
    View in: PubMed
    Score: 0.021
  33. Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):112-8.
    View in: PubMed
    Score: 0.021
  34. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008; 28(2):324-9.
    View in: PubMed
    Score: 0.020
  35. Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study. J Hum Hypertens. 2007 May; 21(5):347-52.
    View in: PubMed
    Score: 0.019
  36. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec; 29(12):2592-7.
    View in: PubMed
    Score: 0.019
  37. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55.
    View in: PubMed
    Score: 0.019
  38. The continuum of blood pressure risk: when is the best time to intervene? Curr Hypertens Rep. 2006 Oct; 8(5):395-7.
    View in: PubMed
    Score: 0.019
  39. Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach. J Cardiometab Syndr. 2006; 1(5):334-42; quiz 343.
    View in: PubMed
    Score: 0.018
  40. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005 Dec; 46(6):1309-15.
    View in: PubMed
    Score: 0.018
  41. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):587-95; quiz 596-7.
    View in: PubMed
    Score: 0.018
  42. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
    View in: PubMed
    Score: 0.017
  43. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications. 2005 Mar-Apr; 19(2):74-9.
    View in: PubMed
    Score: 0.017
  44. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
    View in: PubMed
    Score: 0.017
  45. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10; 292(18):2227-36.
    View in: PubMed
    Score: 0.017
  46. Hypertension control rates: time for translation of guidelines into clinical practice. Am J Med. 2004 Jul 01; 117(1):62-4.
    View in: PubMed
    Score: 0.016
  47. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
    View in: PubMed
    Score: 0.016
  48. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19; 14(3):e076444.
    View in: PubMed
    Score: 0.016
  49. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7.
    View in: PubMed
    Score: 0.016
  50. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731.
    View in: PubMed
    Score: 0.014
  51. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 10 22; 400(10361):1405-1416.
    View in: PubMed
    Score: 0.014
  52. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31.
    View in: PubMed
    Score: 0.014
  53. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37-47.
    View in: PubMed
    Score: 0.014
  54. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens. 2002 Jan; 15(1 Pt 1):53-7.
    View in: PubMed
    Score: 0.014
  55. Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. J Am Heart Assoc. 2021 11 16; 10(22):e022479.
    View in: PubMed
    Score: 0.013
  56. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich). 2001 Jan-Feb; 3(1):16-21.
    View in: PubMed
    Score: 0.013
  57. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep; 36(3):646-61.
    View in: PubMed
    Score: 0.012
  58. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.
    View in: PubMed
    Score: 0.012
  59. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
    View in: PubMed
    Score: 0.011
  60. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933.
    View in: PubMed
    Score: 0.011
  61. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep; 54(3):889-96.
    View in: PubMed
    Score: 0.011
  62. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
    View in: PubMed
    Score: 0.010
  63. Renal components of the hypertensive syndrome. J Cardiovasc Risk. 1997 Aug; 4(4):271-7.
    View in: PubMed
    Score: 0.010
  64. Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701.
    View in: PubMed
    Score: 0.010
  65. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843.
    View in: PubMed
    Score: 0.010
  66. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072.
    View in: PubMed
    Score: 0.009
  67. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072.
    View in: PubMed
    Score: 0.009
  68. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072.
    View in: PubMed
    Score: 0.009
  69. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072.
    View in: PubMed
    Score: 0.009
  70. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr; 34(4):788-97.
    View in: PubMed
    Score: 0.009
  71. Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996 Mar; 36(3):274-9.
    View in: PubMed
    Score: 0.009
  72. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779.
    View in: PubMed
    Score: 0.009
  73. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3):211-21.
    View in: PubMed
    Score: 0.008
  74. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33.
    View in: PubMed
    Score: 0.008
  75. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
    View in: PubMed
    Score: 0.008
  76. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications. 1994 Jan-Mar; 8(1):2-6.
    View in: PubMed
    Score: 0.008
  77. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov; 28(11):2841-50.
    View in: PubMed
    Score: 0.008
  78. Severe hypertension in a young patient. Hosp Pract (Off Ed). 1993 Oct 15; 28(10):57-64.
    View in: PubMed
    Score: 0.008
  79. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8.
    View in: PubMed
    Score: 0.007
  80. Evaluating the role of key learning theories in ECHO: a telehealth educational program for primary care providers. Prog Community Health Partnersh. 2013; 7(4):361-8.
    View in: PubMed
    Score: 0.007
  81. Using an established telehealth model to train urban primary care providers on hypertension management. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):45-50.
    View in: PubMed
    Score: 0.007
  82. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1.
    View in: PubMed
    Score: 0.007
  83. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S24-31.
    View in: PubMed
    Score: 0.006
  84. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16.
    View in: PubMed
    Score: 0.006
  85. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20.
    View in: PubMed
    Score: 0.006
  86. Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. Intern Med J. 2010 Dec; 40(12):833-41.
    View in: PubMed
    Score: 0.006
  87. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol. 2010 Dec; 21(12):2131-42.
    View in: PubMed
    Score: 0.006
  88. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29.
    View in: PubMed
    Score: 0.006
  89. Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP). Diabetes Care. 2010 Dec; 33(12):2586-91.
    View in: PubMed
    Score: 0.006
  90. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med. 1990 Jul 12; 323(2):86-90.
    View in: PubMed
    Score: 0.006
  91. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 05; 102(9):596-604.
    View in: PubMed
    Score: 0.006
  92. The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy. J Clin Pharmacol. 1990 Feb; 30(2):155-8.
    View in: PubMed
    Score: 0.006
  93. Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):51-8.
    View in: PubMed
    Score: 0.006
  94. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
    View in: PubMed
    Score: 0.006
  95. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
    View in: PubMed
    Score: 0.006
  96. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008 Aug; 156(2):277-83.
    View in: PubMed
    Score: 0.005
  97. A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure. Am J Cardiol. 2008 Jun 15; 101(12):1772-6.
    View in: PubMed
    Score: 0.005
  98. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S46-55.
    View in: PubMed
    Score: 0.005
  99. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation. 2008 Apr 01; 117(13):1685-92.
    View in: PubMed
    Score: 0.005
  100. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Feb; 51(2):192-8.
    View in: PubMed
    Score: 0.005
  101. Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man. Miner Electrolyte Metab. 1988; 14(6):343-6.
    View in: PubMed
    Score: 0.005
  102. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7.
    View in: PubMed
    Score: 0.005
  103. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
    View in: PubMed
    Score: 0.005
  104. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9.
    View in: PubMed
    Score: 0.005
  105. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92.
    View in: PubMed
    Score: 0.005
  106. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9.
    View in: PubMed
    Score: 0.005
  107. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007 Jul; 120(7):610-5.
    View in: PubMed
    Score: 0.005
  108. beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab. 2007 May; 9(3):408-17.
    View in: PubMed
    Score: 0.005
  109. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care. 2007 Apr; 30(4):995-6.
    View in: PubMed
    Score: 0.005
  110. The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol. Circulation. 1986 Nov; 74(5):1061-5.
    View in: PubMed
    Score: 0.005
  111. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3.
    View in: PubMed
    Score: 0.005
  112. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
    View in: PubMed
    Score: 0.005
  113. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
    View in: PubMed
    Score: 0.004
  114. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005 Jun; 18(6):797-804.
    View in: PubMed
    Score: 0.004
  115. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005 Apr; 67(4):1483-8.
    View in: PubMed
    Score: 0.004
  116. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6):1206-52.
    View in: PubMed
    Score: 0.004
  117. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9.
    View in: PubMed
    Score: 0.004
  118. Pulmonary scar carcinoma. A clinicopathologic analysis. Cancer. 1983 Aug 01; 52(3):493-7.
    View in: PubMed
    Score: 0.004
  119. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
    View in: PubMed
    Score: 0.004
  120. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72.
    View in: PubMed
    Score: 0.004
  121. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003 Jun; 16(6):460-6.
    View in: PubMed
    Score: 0.004
  122. Disopyramide-associated liver dysfunction. Mayo Clin Proc. 1983 Apr; 58(4):265-7.
    View in: PubMed
    Score: 0.004
  123. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
    View in: PubMed
    Score: 0.004
  124. The use of clonidine for management of opiate abstinence in a chronic pain patient. Mayo Clin Proc. 1982 Oct; 57(10):657-60.
    View in: PubMed
    Score: 0.004
  125. An effective alternative for muscle contraction headaches. Orphenadrine citrate. IMJ Ill Med J. 1982 Feb; 161(2):106-8.
    View in: PubMed
    Score: 0.003
  126. Psychogenic vertigo: a review. Postgrad Med. 1981 Nov; 70(5):69-71, 74, 77.
    View in: PubMed
    Score: 0.003
  127. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28.
    View in: PubMed
    Score: 0.003
  128. Lithium prophylaxis and the kidney. J Affect Disord. 1981 Mar; 3(1):37-42.
    View in: PubMed
    Score: 0.003
  129. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000 Feb 28; 160(4):481-90.
    View in: PubMed
    Score: 0.003
  130. Dermatologic manifestations of lithium: a review. Int J Psychiatry Med. 1980-1981; 10(4):327-31.
    View in: PubMed
    Score: 0.003
  131. A liquid chromatographic assay for 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in human body fluids. Acta Pharmacol Toxicol (Copenh). 1982 Nov; 51(5):421-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.